<DOC>
	<DOC>NCT03064438</DOC>
	<brief_summary>The study evaluates the safety, efficacy and tolerability of ACCU-D1 when applied twice daily for 12 weeks in adult patients with moderate to severe acne rosacea. Two thirds of participants will receive ACCU-D1 while one third will receive vehicle control.</brief_summary>
	<brief_title>Efficacy of Accu-D1 in the Treatment of Acne Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>Patient is male or nonpregnant female at least 18 years of age Patient has ten to forty inflammatory lesions of rosacea on the face at Randomization Clinical diagnosis of mild to severe facial rosacea as determined by Investigator's Global Assessment (IGA) at Randomization A score of greater than moderate on the Clinical Erythema Assessment Scale Informed consent obtained from subject and a copy of the signed consent provided to subject Patient is pregnant or planning to become pregnant Patient is taking a topical or oral therapy which may affect the patient's rosacea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>